Navigation Links
First Bedside DNA Test to be Distributed by Chirus in UK
Date:12/27/2012

Ottawa, Ontario (PRWEB) December 27, 2012

Spartan Bioscience today announced a distribution agreement with Chirus for the Spartan RX—the first point-of-care DNA test in medicine.(1) Chirus specializes in point-of-care diagnostic products in the UK.

The Spartan RX point-of-care DNA testing system identifies carriers of CYP2C19 loss-of-function mutations, which are carried by approximately 30% of the world’s population.(2) Genetic carriers who receive Plavix® (clopidogrel) following a cardiac stent have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) In 2009, Plavix® was the second best-selling drug in the world, with over $9 billion in revenues.

“Spartan is very excited to extend its distribution network to the UK,” said Paul Lem, M.D., CEO of Spartan Bioscience. “We have chosen Chirus as our partner based on their market development expertise and existing customer base.”

“The Spartan RX system is a breakthrough towards bringing rapid genomic testing to the point of care,” said Talat Syed, Director of Chirus. “For the first time, cardiologists can genotype patients in the cardiac catheterization suite.”

About the Spartan RX CYP2C19
The Spartan RX CYP2C19 is the first point-of-care DNA test in medicine.(1) It identifies carriers of CYP2C19 genetic mutations in 1 hour. These mutations are carried by approximately 30 percent of the world’s population.(2) Genetic carriers who receive Plavix® following a cardiac stent insertion to open clogged arteries have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) Currently, genetic testing is performed in central labs and it takes up to seven days to get a test result back. A rapid test is needed because most of the complications for CYP2C19 car
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
8. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. Amgen Announces 2012 First Quarter Dividend
11. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 2014 Deep ... is a professional and in-depth research report ... provides basic Seaweed Fertilizer information, including Seaweed ... structure as well as industry overview. This ... domestic market as well as global industry ...
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)... NJ (PRWEB) August 21, 2014 ... personal selling optimization technology and services for Life ... of “Grading Pharma’s Use of New Commercial Sales ... Measurement & Analytics. , The article examines some ... yield that are being tested in the pharmaceutical ...
(Date:8/20/2014)... 2014 Clintrax Global, Inc., a worldwide ... Raleigh, NC , recently announced the ... President of Administration. As Vice ... processes, including their alignment with company objectives and ... as an HR executive, specializing in needs assessments, ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2
... EMERYVILLE, Calif., Jan. 2 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... present,at the JPMorgan Healthcare Conference on Monday, January ... access a live webcast of the,presentation at:, ... listeners log on 15 minutes early in order ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... has filed a protocol with the U.S. ... 1/2 clinical trial for patients with,metastatic ovarian, ... and intraperitoneal administration of REOLYSIN(R), Oncolytics,proprietary formulation ...
... LOS GATOS, Calif., Dec. 31 Three ... announced that it has received 510(k) clearance,from ... for its WorkstationOne(TM),Breast Imaging Workstation. WorkstationOne is ... mammography images, and was developed with,the goal ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R) 2
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... sunscreen and seawater signals a relaxing trip to the ... beach vacation comes with an environmental hitch. When certain ... they can become toxic to some of the ocean,s ... other marine animals. Their study appears in the ACS ... Tovar-Sanchez and David Snchez-Quiles point out that other than ...
(Date:8/20/2014)... Wu Feng has built upon a National Science Foundation ... Cloud" program, and synergistically complemented it with subsequent collaborative ... Force on "big computing" for mini-drones and a $1 ... Health on "big data" for the life sciences. , ... each grant, he was able to tell a much ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... are under attack. Since 2006, more than a million have ... there has not been enough evidence to implicate the suspectuntil ... Geomyces destructans is the causal agent of White-nose Syndrome (WNS), ... is coauthored by Justin Boyles, a post-doctoral research associate in ...
... Dalhousie University in Nova Scotia have identified a key ... growth if their findings are confirmed. In ... journal of the American Association for Cancer Research, lead ... Biochemistry and Molecular Biology and Pathology, and Canada Research ...
... alphabet expanded. Scientists discovered that an extra letter or ... cells and brain cells. Now, researchers at Emory ... by that letter in the brains of mice, observing ... during development and aging. Those patterns, stable or ...
Cached Biology News:UT scientist helps confirm link between fungus and bat epidemic 2Key driver of metastasis identified 2Patterns of new DNA letter in brain suggest distinct function 2
Recombinant Feline IFN-alpha...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
... MaV203 Competent Yeast Cells are designed ... (Figure 1). S. cerevisiae strain MaV203 contains ... genes for use with GAL4-based two-hybrid systems. ... mutations for selection of ProQuest bait and ...
Biology Products: